Commenters to the FDA also advocated for safety reforms and for industry funds to be used for post-market monitoring.
Patients call for more medical device user fee funding, FDA staffing Read More »
The biopharma job market remains challenging, based on BioSpace data. In August, job postings live on the website dropped 32% year over year. In addition, during the first eight months of 2025, over 26,000 people were laid off or projected to be laid off.
Hiring Outlook: Fewer Job Openings, High Competition Await Biopharma Job Seekers Read More »
Chair Andrew Ferguson has sent letters to large healthcare employers and staffing firms asking them to review their employment contracts as the FTC pursues targeted enforcement of illegal noncompetes.
FTC warns healthcare companies about restrictive noncompete contracts Read More »
A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry’s ability to buy new molecules from biotechs based in China, along with a number of other proposed reforms.
Trump Reportedly Preparing Order Restricting Chinese Drug Licensing Deals Read More »
The nonprofit giant plans to step into northern Nevada next year by partnering with regional system Renown. The deal includes a majority investment in Renown’s health plan, though financial terms were not disclosed.
Kaiser Permanente to expand into Nevada through joint venture with Renown Health Read More »
Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy.
Capsida Reports Patient Death in Gene Therapy Trial Read More »
New York City has seen increased life sciences employment during the past decade as public funding and key projects like JLABS @ NYC have given the area a boost. A Partnership Fund for New York City executive discusses the city’s strengths and a notable challenge facing businesses.
New York City’s Life Sciences Scene Grows in Stature Read More »
The influential senator argued the technology giant delivered “dangerous, insecure software” to the health system that contributed to a massive cyberattack last year.
Wyden urges FTC to investigate Microsoft over Ascension cyberattack Read More »
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA Read More »
New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain.
FDA Looks to Streamline Development of Non-Opioid Painkillers Read More »
